RXI-109 / Phio Pharma - LARVOL DELTA

RXi Pharmaceuticals announces Investor and Analyst Symposium (RXi Pharma) - "RXi Pharmaceuticals...announced that it will hold its first Investor and Analyst Symposium...'RXi Pharmaceuticals will have the complete unblinded data of their two Phase 1 studies available around the middle of this year'...'At this Investor and Analyst Symposium, we expect to announce the formal transition of RXI-109 into a Phase 2 clinical development program, and also provide more detail on the indications and patient population we will target in our Phase 2 studies."

Anticipated conference • Anticipated P1 data • Anticipated pipeline update • Fibrosis

RXi Pharmaceuticals announces upcoming presentations (RXi Pharma Press Release) - During 72nd Annual Meeting of the American Academy of Dermatology on Mar 22, 2014 Dr. Lyn Libertine and Dr. Pavco will present P1 data of RXI-109.

Anticipated conference • Anticipated P1 data • Fibrosis

RXi Pharmaceuticals to present at 11th Annual BIO Investor Forum (RXi Pharma) - RXi Pharma will discuss the development of RXI-109 & business development opportunities with RXi’s sd‑rxRNA technology platform at the 11th Annual BIO Investor Forum on Wednesday, October 10, 2012

Anticipated conference • Fibrosis

RXi Pharmaceuticals reports full year 2012 financial results (RXi Pharma) - " '...in the 1st quarter of 2013, to acquire substantially all of the siRNA assets of OPKO while also having OPKO, Frost Gamma Investments Trust and other premier investment funds become shareholders of RXi through a private placement. This financing will provide us with the necessary cash to comfortably move RXI-109 into Phase 2 clinical trials.' "

Anticipated new P2 trial • Anticipated phase shift • Financing • Fibrosis

RXi Pharmaceuticals granted key patent related to self-delivering technology for the treatment of fibrotic disorders (RXi Pharma Press Release) - "RXi Pharmaceuticals Corporation...announced that it has been granted a patent by the U.S. Patent and Trademark Office on its unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI‑109, for the treatment of fibrotic disorders. U.S. Patent Number 8,664,189, will expire in 2029."

Patent • Fibrosis

Prevention of uvr induced mmp1 upregulation with mmp1 targeting self-delivering rnai (sd-rxrna) compounds may reduce the effects of skin photoaging (SID 2017) - "Solar UVA and UVB irradiation, are the causative factors for sunlight induced skin photoaging. Others have repeatedly shown, reducing the available collagenase restricts the ability of these cancer cells to effectively migrate through the Collagen 1 based ECM. The ability of RXI-185 to effect the migration rates of UVR treated fibroblasts will be further discussed."

Preclinical • Biosimilar • Melanoma • Oncology • Ophthalmology

RXI Pharmaceuticals could benefit from biotech industry dynamics (Biotech stock trader) - "RXi Pharmaceuticals recently reported positive results for its first and second Phase I multi-dose study of RXI-109...shares are trading up more than 40% over the past month with these positive results in hand."; Anticipated new P2 study.

Anticipated new P2 trial • Stock price • Fibrosis

RXi Pharmaceuticals to present at the Biotech Showcase 2014 (RXi Pharma Press Release) - "RXi Pharmaceuticals Corporation...announced that the Company’s President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the Biotech Showcase™ 2014 conference on Tuesday, January 14, 2014 at 9:30AM PST. Dr. Cauwenbergh will discuss the development of RXI-109..."

Anticipated conference • Fibrosis

Visualization of self-delivering hydrophobically modified siRNA cellular internalization. (PubMed) - Nucleic Acids Res - "Here we study the mechanism of internalization of asymmetric, chemically stabilized, cholesterol-modified siRNAs (sd-rxRNAs(®)) that efficiently enter cells and tissues without the need for formulation. However, the mechanistic role of EEA1 is not yet known. This method of visualization can be used to better understand the kinetics and mechanisms of hydrophobic siRNA cellular uptake and will assist in further optimization of these types of compounds for therapeutic intervention."

Journal • Biosimilar

Rxi Pharmaceuticals, significant upside of 300% is expected in coming months (SeekingAlpha) - Anticipated P1 additional cohort results in Dec 2013; Anticipated two phase 2 trials to begin either by the end of 2013, or Q1 of 2014.

Anticipated new P2 trial • Anticipated P1 data • Fibrosis

Evaluation of the safety, pharmacokinetics, and preliminary effect on scar formation by RXI-109 (clinicaltrials.gov) - P1, N=20; Recruiting; New P1 trial

New P1 trial • Fibrosis

RXI Pharmaceuticals' (RXII) CEO Geert Cauwenbergh on Q2 2016 results - earnings call transcript (SeekingAlpha) - "...our ocular program...to provide initial safety readouts from our Phase I/II study, because this is in-patients not in healthy volunteers...dermal scarring trial with RXI-109 Study 1402 will be completely enrolled and dates for scar revision surgery set. Our goal is to enroll by the end of this year, so we are about four months ahead of schedule... Our estimates to complete the full analysis for Study 1402 is in the third quarter of 2017."

Anticipated enrollment status • Anticipated P1/2 data • Age-related Macular Degeneration • Fibrosis • Ophthalmology

RXi Pharmaceuticals receives FDA clearance to begin clinical trial with RXI-109 (RXi Pharma) - RXi Pharmaceuticals announced that it has received clearance for its IND from the US FDA to initiate clinical trials with RXI-109; The Phase 1 trial will investigate the compound in subjects to evaluate its safety and tolerability, and to look for surrogate parameters that might predict the potential of the compound to reduce dermal scarring in planned surgeries

Anticipated P1 trial • IND approval • Fibrosis

RXi Pharmaceuticals appoints industry veteran Dr. Geert Cauwenbergh as President and Chief Executive Officer (RXi Pharma) - Anticipated progress of RXI-109 into human clinical trials in 2012

Anticipated clinical development • Fibrosis

RXi Pharmaceuticals announces initiation of first clinical trial (RXi Pharma) - RXi Pharmaceuticals successfully initiated its first ever clinical study with RXI-109, using their proprietary self-delivering RNAi technology; After completion of the necessary toxicological studies & clearance of their IND submission by the USFDA, they have now successfully dosed their first subject in a dose escalation study

Clinical • Fibrosis

Phio Pharmaceuticals announces research collaboration with Carisma Therapeutics to evaluate its self-delivering RNAi technology to enhance macrophage-based adoptive cell therapy (PRNewswire) - "Phio Pharmaceuticals Corp...a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced....that it has entered into a research collaboration with Carisma Therapeutics to evaluate the potential of Phio's self-delivering RNAi compounds to synergistically modify Carisma's chimeric antigen receptor macrophages (CAR-M)."

Licensing / partnership

Phio Pharmaceuticals and Helmholtz Zentrum München to collaborate on novel targets for the use of self-delivering RNAi in T cell and NK cell adoptive cell therapy therapeutics (PRNewswire) - “Phio Pharmaceuticals Corp….announced today that is has entered into a research collaboration with the Helmholtz Zentrum München. The agreement covers the design and development of new targets based on Phio Pharmaceuticals' proprietary self-delivering RNAi platform for use in cancer immunotherapies.”

Licensing / partnership

Phio Pharmaceuticals reports fourth quarter and year end 2018 financial results and corporate highlights (RXi Pharma Press Release) - "Study RXI-109-1501, a Phase 1/2 clinical trial for retinal scarring in subjects with wet age-related macular degeneration with evidence of subretinal fibrosis, successfully met its primary objective as shown by the absence of dose-limiting and serious toxicities. The secondary objective of the study was also met with improved or stable disease in the study eyes of several subjects."

P1/2 data